Abstract
It was in the year 1955 that Andrew Schally proved the existence of hypothalamic hormones regulating pituitary function, as Geoffrey Harris had postulated with prophetic insight. Two years later, in 1957, Schally continued his work at Baylor University College of Medicine in Houston, Texas, where he associated with Charles Guillemin. During this 2-year period, these three Nobel laureates settled the basis of somatostatin receptors’ analogues. This chapter presents a brief history of somatostatin, its receptors and analogues.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Obituary notices. Br Med J 1971; 4:628. https://doi.org/10.1136/bmj.4.5787.628.
Public domain; http://resource.nlm.nih.gov/101441443
CREDIT Phil Jones, GHSU Photographer, usage restrictions none; https://www.eurekalert.org/multimedia/pub/web/40267_web.jpg
Karfis I. PhD thesis, Medical School, National and Kapodistrian University of Athens-Greece; 2016.
Harris GW. Neural control of the pituitary gland. Monographs of the Physiological Society 3. London: Edward Arnold Publishers Ltd; 1955. p. 298.
Green JD, Harris GW. The neurovascular link between the neuro-hypophysis and the adenohypophysis. J Endocrinol. 1947;5:136–46.
Harris GW. Humours and hormones. The Sir Henry Dale Lecture for 1971. J Endocrinol. 1972;53:1–23.
Raisman G. An urge to explain the incomprehensible: Geoffrey Harris and the discovery of the neural control of the pituitary gland. Annu Rev Neurosci. 1997;20:533–66.
Burgus R, Dunn TF, Desiderio D, et al. Molecular structure of the hypothalamic hypophysiotropic TRF factor of ovine origin: mass spectrometry demonstration of the PCA-His-Pro-NH2 sequence. Comptes Rendus Hebdomadaires des Séances de l’ Académie des Sci. 1969;269:1870–3.
Schally AV, Redding TW, Bowers CY, et al. Isolation and properties of porcine thyrotropin-releasing hormone. J Biol Chem. 1969;244(15):4077–88.
Krulich L, Dhariwal AP, McCann S. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vivo. Endocrinology. 1968;83:783–90.
Hellman B, Lernmark A. Inhibition of the in vitro secretion of insulin by an extract of pancreatic alpha-1 cells. Endocrinology. 1969;84:1484–8.
Edman P. Method for determination of the amino acid sequence in peptides. Acta Chem Scand. 1950;4:283–93.
Guillemin R. Peptides in the brain. The new endocrinology of the neuron. Nobel Lecture; 1977.
Guillemin R. Hypothalamic hormones a.k.a. hypothalamic releasing factors. J Endocrinol. 2005;184:11–28.
Guillemin R. Somatostatin. The beginnings, 1972. Mol Cell Endoc. 2008;286:3–4.
Guillemin R. Neuroendocrinology: a short historical review. Ann N Y Acad Sci. 2011;1220:1–5.
Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179:71–9.
Koerker DJ, Ruch W, Chideckel E. Somatostatin: hypothalamic inhibitor of the endocrine pancreas. Science. 1974;184:482–4.
Dubois MP. Immunoreactive somatostatin is present in discrete cells of the endocrine pancreas. Proc Natl Acad Sci U S A. 1975;72(4):1340–3.
Hökfelt T, Efendić S, Hellerström C, et al. Cellular localization of somatostatin in endocrine-like cells and neurons of the rat with special references to the A1-cells of the pancreatic islets and to the hypothalamus. Acta Endoc Suppl (Copenh). 1975;200:5–41.
Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157–98.
Taniyama Y, Suzuki T, Mikami Y, et al. Systemic distribution of somatostatin receptor subtypes in human: an immuno-histochemical study. Endocr J. 2005;52(5):605–11.
Sheppard MC, Shapiro B, Pimstone BL, et al. Metabolic clearance and plasma half disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab. 1979;48:50–3.
Ho LT, Chen RL, Chou TY, et al. Pharmacokinetics and effects of intravenous infusion of somatostatin in normal subjects—a two-compartment open model. Clin Physiol Biochem. 1968;4(4):257–67.
Hildebrand P, Ensinck JW, Buettiker J, et al. Circulating somatostatin-28 is not a physiologic regulator of gastric acid production in man. Eur J Clin Inv. 1994;24(1):50–6.
Rivier J, Brown M, Vale W. D-Trp8-somatostatin: an analog of somatostatin more potent than the native molecule. Biochem Biophys Res Commun. 1975;65(2):746–51.
Janecka A, Zubrzycka M, Janecki T. Somatostatin analogs. J Pept Res. 2001;58(2):91–107.
Mazziotti G, Mosca A, Frara S, et al. Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects. Expert Opin Pharmacother. 2017;18:1679–89.
Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–33.
Vitale G, Dicitore A, Sciammarella C, et al. Pasireotide in the treatment of neuroendocrine tumors: a review of the literature. Endo Related Cancer. 2018;25:R351–64. https://doi.org/10.1530/erc-18-0010.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Limouris, G.S. (2021). Somatostatin. In: Limouris, G.S. (eds) Liver Intra-arterial PRRT with 111In-Octreotide. Springer, Cham. https://doi.org/10.1007/978-3-030-70773-6_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-70773-6_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-70772-9
Online ISBN: 978-3-030-70773-6
eBook Packages: MedicineMedicine (R0)